...

Deaths of Children in Uzbekistan Linked to Indian Cough Syrup and Regulatory Failures

Over 18 children die in Uzbekistan linked to Indian cough syrup; court cites regulatory failures and safety negligence.

2 min read

Indian Cough Syrup Uzbek Tragedy

Indian-manufactured cough syrup linked to child deaths in Uzbekistan; regulators under scrutiny for safety lapses [IC : by AFP]

February 20, 2026

New Delhi, February 20, 2026 – India is once again under the spotlight for alleged regulatory failures after cough syrups manufactured by an Indian pharmaceutical firm were linked to the deaths of more than 18 children in Uzbekistan. The Supreme Court of India reprimanded the company, highlighting the grave damage inflicted on the country’s international image due to negligence in drug safety.

A bench led by Chief Justice Surya Kant questioned how such lapses could occur in a country that exports medicines worldwide, pointing to serious lapses in quality control and oversight. The court refused to quash an order summoning the company and its officials, following a complaint that the drugs were “not of standard quality” and violated key provisions of the Drugs and Cosmetics Act, 1940.

Despite repeated warnings, the company and its representatives appeared to downplay the issue, claiming there was no direct evidence linking the syrup to the children’s deaths. The bench dismissed this defense, stressing that the failure to ensure safety not only cost lives but also tarnished India’s credibility as a reliable producer of pharmaceuticals.

Legal experts and international observers say this incident exposes systemic weaknesses in India’s drug regulatory framework, and raises serious questions about the effectiveness of enforcement mechanisms meant to prevent such tragedies. The court’s remarks underline that profit-driven negligence cannot be tolerated when public health, especially the lives of children abroad, is at stake.

Uzbekistan authorities had confirmed that the syrup was toxic, and the deaths triggered international concern, putting India’s pharmaceutical exports under scrutiny. The Supreme Court emphasized that accountability must extend to company leadership, regulatory bodies, and government oversight agencies to prevent further loss of life and reputational damage.

This case reflects a larger pattern of concern over India’s pharmaceutical safety standards, where commercial interests appear to outweigh public health, leading to preventable tragedies and straining diplomatic relations.

Related Articles

Reports allege Taliban detained and tortured 13 people in Badakhshan over ISIS-K claims amid rising internal tensions.
Two Taliban members killed in armed clash between rival factions in Badakhshan, raising concerns over internal divisions.
PM Shehbaz Sharif arrives in Doha on official visit, receives warm welcome; key talks with Qatari Emir expected.

Post a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Seraphinite AcceleratorOptimized by Seraphinite Accelerator
Turns on site high speed to be attractive for people and search engines.